Beyondspring (BYSI) AI Stock Analysis

• Market Cap: $81.04M
• Dividend Yield: N/A
• Average Volume (3M): 22.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): 0.11
• Shares Outstanding: 40,316,320
• 10 Day Avg. Volume: 19,300
• 30 Day Avg. Volume: 22,743
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: -69.85
• Enterprise Value/Gross Profit: -69.85
• Enterprise Value/Ebitda: -18.31
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ―

Beyondspring's overall stock score reflects its significant financial challenges, with zero revenue and negative margins indicating severe financial distress. While technical analysis shows some positive short-term momentum, the stock is nearing overbought conditions. The negative P/E ratio highlights overvaluation concerns, significantly impacting the overall score.

Beyondspring Business Overview & Revenue Model

Company Description

BeyondSpring Inc. (NASDAQ: BYSI) is a global biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. Headquartered in New York City, the company is dedicated to improving clinical outcomes for patients with high unmet medical needs. BeyondSpring's lead asset, Plinabulin, is a first-in-class immune-oncology agent that is being developed as a potential treatment for chemotherapy-induced neutropenia and non-small cell lung cancer. The company's pipeline includes additional oncology assets in various stages of development.

How the Company Makes Money

BeyondSpring generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to bring its products to market through a combination of direct commercialization, partnerships, and licensing agreements with other pharmaceutical companies. Revenue streams include milestone payments and royalties from partnerships, as well as potential sales revenue from its lead product, Plinabulin, once it receives regulatory approval and is commercialized. BeyondSpring may also receive funding through research grants and collaborations with academic and research institutions.

Beyondspring Financial Statement Overview

Summary

Beyondspring's financial statements reveal a company under considerable financial strain. With zero revenue in 2024, negative profit margins, and declining assets, the company faces significant challenges in achieving profitability and financial stability. The reliance on financing for cash flow suggests a precarious financial position, requiring strategic shifts to improve operational efficiency and revenue generation.

Income Statement

The company's income statement reveals several challenges. Total revenue dropped to zero in 2024 from $1.75 million in 2023, indicating a declining trend. Gross profit margin is non-existent due to zero revenue. Moreover, net profit margin is severely negative at -100% in 2024, with EBIT and EBITDA margins also in negative territory, pointing to significant operational losses. There is no revenue growth, which is concerning for future sustainability.

Balance Sheet

The balance sheet shows financial instability with negative stockholders' equity of $32.9 million in 2024, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated reliably due to negative equity, suggesting high leverage and financial risk. Total assets have decreased over the years, and the equity ratio is negative, highlighting significant financial distress.

Cash Flow

Cash flow analysis indicates ongoing operational challenges. Operating cash flow remains negative, though slightly improved from the previous year. The free cash flow is also negative, showing that the company is not generating sufficient cash to cover investments. Financing cash flow is positive, primarily due to new financing activities, suggesting reliance on external funding to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	1.75M	1.35M	1.35M	180.00K
Gross Profit	0.00	1.75M	1.35M	1.35M	103.00K
EBITDA	-8.48M	-21.54M	-34.96M	-64.49M	-63.66M
Net Income	-11.12M	-21.03M	-36.28M	-68.21M	-61.06M
Balance Sheet
Total Assets	34.31M	24.81M	46.22M	81.65M	117.04M
Cash, Cash Equivalents and Short-Term Investments	2.92M	8.00M	37.27M	72.37M	109.54M
Total Debt	589.00K	4.00M	4.96M	3.58M	4.31M
Total Liabilities	48.60M	48.27M	49.23M	60.73M	30.41M
Stockholders Equity	-32.90M	-26.80M	-5.98M	26.68M	88.34M
Cash Flow
Free Cash Flow	-16.67M	-16.57M	-27.50M	-50.09M	-43.80M
Operating Cash Flow	-16.44M	-16.47M	-27.46M	-47.24M	-43.74M
Investing Cash Flow	-12.01M	-100.00K	17.56M	-20.41M	-52.00K
Financing Cash Flow	26.79M	4.00K	3.43M	1.00K	117.83M

Beyondspring Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.01
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BYSI, the sentiment is Negative. The current price of 2.01 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.26, and above the 200-day MA of 1.83, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.53 is Neutral, neither overbought nor oversold. The STOCH value of 30.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BYSI.

Beyondspring Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DTIL	51 Neutral	$51.63M	2.40	-143.89%	―	-98.56%	-347.81%
Sector *	47 Neutral	C$212.69M	-2.68	-24.76%	3.10%	19.76%	0.48%
BYSI	44 Neutral	$81.04M	―	78.44%	―	―	―
MAIA	44 Neutral	$51.80M	―	-459.53%	―	―	62.69%
IMA	41 Neutral	$164.04M	―	-23.76%	―	-100.00%	55.32%
ACRV	36 Underperform	$39.19M	―	-62.41%	―	―	22.94%
ACET	27 Underperform	$49.65M	―	-64.39%	―	―	48.45%